AU2013215886B2 - Anti-phospholipase D4 antibody - Google Patents
Anti-phospholipase D4 antibody Download PDFInfo
- Publication number
- AU2013215886B2 AU2013215886B2 AU2013215886A AU2013215886A AU2013215886B2 AU 2013215886 B2 AU2013215886 B2 AU 2013215886B2 AU 2013215886 A AU2013215886 A AU 2013215886A AU 2013215886 A AU2013215886 A AU 2013215886A AU 2013215886 B2 AU2013215886 B2 AU 2013215886B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- pld4
- cell
- sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018200934A AU2018200934B2 (en) | 2012-01-31 | 2018-02-08 | Anti-phospholipase D4 antibody |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-018266 | 2012-01-31 | ||
| JP2012018266 | 2012-01-31 | ||
| PCT/JP2013/052781 WO2013115410A2 (en) | 2012-01-31 | 2013-01-31 | Anti-phospholipase d4 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018200934A Division AU2018200934B2 (en) | 2012-01-31 | 2018-02-08 | Anti-phospholipase D4 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013215886A1 AU2013215886A1 (en) | 2014-08-14 |
| AU2013215886B2 true AU2013215886B2 (en) | 2017-11-09 |
Family
ID=47748721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013215886A Active AU2013215886B2 (en) | 2012-01-31 | 2013-01-31 | Anti-phospholipase D4 antibody |
| AU2018200934A Active AU2018200934B2 (en) | 2012-01-31 | 2018-02-08 | Anti-phospholipase D4 antibody |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018200934A Active AU2018200934B2 (en) | 2012-01-31 | 2018-02-08 | Anti-phospholipase D4 antibody |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9944715B2 (https=) |
| EP (2) | EP2809683B1 (https=) |
| JP (4) | JP6118345B2 (https=) |
| KR (1) | KR102098413B1 (https=) |
| CN (2) | CN104284903B (https=) |
| AU (2) | AU2013215886B2 (https=) |
| CA (1) | CA2863009C (https=) |
| DK (2) | DK3431504T3 (https=) |
| ES (2) | ES2694165T3 (https=) |
| HU (2) | HUE054362T2 (https=) |
| IL (1) | IL233794B (https=) |
| PL (2) | PL2809683T3 (https=) |
| PT (1) | PT2809683T (https=) |
| TR (1) | TR201819828T4 (https=) |
| WO (1) | WO2013115410A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2809683T3 (pl) * | 2012-01-31 | 2019-03-29 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| PL3027656T3 (pl) * | 2013-07-30 | 2019-10-31 | Sbi Biotech Co Ltd | Lek zawierający przeciwciało anty-fosfolipazowe D4 |
| CN109535254B (zh) * | 2013-12-24 | 2022-06-24 | 安斯泰来制药株式会社 | 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物 |
| US10759859B2 (en) | 2016-01-14 | 2020-09-01 | Bps Bioscience, Inc. | Anti-PD-1 antibodies and uses thereof |
| AU2017231833B2 (en) | 2016-03-10 | 2024-03-14 | Viela Bio, Inc. | ILT7 binding molecules and methods of using the same |
| CN105624325B (zh) * | 2016-03-31 | 2019-06-11 | 北京泱深生物信息技术有限公司 | 肺腺癌的诊治标记物 |
| PL3691692T3 (pl) * | 2017-10-14 | 2021-07-19 | Abbvie Inc. | Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania |
| CN110042123B (zh) * | 2019-01-07 | 2023-01-17 | 西北农林科技大学 | 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法 |
| WO2025085746A1 (en) * | 2023-10-18 | 2025-04-24 | Immunorx Pharma Inc. | Humanized anti-s100a9 antibody |
| CN119120388A (zh) * | 2024-10-22 | 2024-12-13 | 江苏亲科生物研究中心有限公司 | 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098015B2 (en) * | 1999-06-11 | 2006-08-29 | Millennium Pharmaceuticals, Inc. | 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor |
| WO2004050850A2 (en) | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
| SI1674111T1 (sl) * | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| PL2809683T3 (pl) * | 2012-01-31 | 2019-03-29 | Sbi Biotech Co., Ltd. | Przeciwciało przeciwko fosfolipazie D4 |
| PL3027656T3 (pl) * | 2013-07-30 | 2019-10-31 | Sbi Biotech Co Ltd | Lek zawierający przeciwciało anty-fosfolipazowe D4 |
-
2013
- 2013-01-31 PL PL13705843T patent/PL2809683T3/pl unknown
- 2013-01-31 AU AU2013215886A patent/AU2013215886B2/en active Active
- 2013-01-31 KR KR1020147023620A patent/KR102098413B1/ko active Active
- 2013-01-31 US US14/375,266 patent/US9944715B2/en active Active
- 2013-01-31 TR TR2018/19828T patent/TR201819828T4/tr unknown
- 2013-01-31 HU HUE18188036A patent/HUE054362T2/hu unknown
- 2013-01-31 CA CA2863009A patent/CA2863009C/en active Active
- 2013-01-31 JP JP2014554166A patent/JP6118345B2/ja active Active
- 2013-01-31 CN CN201380018285.5A patent/CN104284903B/zh active Active
- 2013-01-31 PT PT13705843T patent/PT2809683T/pt unknown
- 2013-01-31 DK DK18188036.0T patent/DK3431504T3/da active
- 2013-01-31 EP EP13705843.4A patent/EP2809683B1/en active Active
- 2013-01-31 EP EP18188036.0A patent/EP3431504B1/en active Active
- 2013-01-31 PL PL18188036T patent/PL3431504T3/pl unknown
- 2013-01-31 HU HUE13705843A patent/HUE041552T2/hu unknown
- 2013-01-31 ES ES13705843.4T patent/ES2694165T3/es active Active
- 2013-01-31 DK DK13705843.4T patent/DK2809683T3/en active
- 2013-01-31 WO PCT/JP2013/052781 patent/WO2013115410A2/en not_active Ceased
- 2013-01-31 ES ES18188036T patent/ES2873035T3/es active Active
- 2013-01-31 CN CN202011128007.3A patent/CN112442128B/zh active Active
-
2014
- 2014-07-24 IL IL233794A patent/IL233794B/en active IP Right Grant
-
2017
- 2017-03-24 JP JP2017058867A patent/JP2017155045A/ja active Pending
-
2018
- 2018-02-08 AU AU2018200934A patent/AU2018200934B2/en active Active
- 2018-03-02 US US15/910,206 patent/US10336834B2/en active Active
- 2018-11-27 JP JP2018220873A patent/JP6830471B2/ja active Active
-
2020
- 2020-10-28 JP JP2020180164A patent/JP7244102B2/ja active Active
Non-Patent Citations (2)
| Title |
|---|
| FUMIO YOSHIKAWA et al PLoS one, Vol. 5, Issue 11, article e13932. November 2010. * |
| YOSHINORI OTANI et al PLoS one, Vol. 6, Issue 11, article e27544. November 2011. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018200934B2 (en) | Anti-phospholipase D4 antibody | |
| JP6412072B2 (ja) | 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 | |
| JP5420688B2 (ja) | 抗ｉｌｔ７抗体 | |
| JP2019214621A (ja) | 抗ホスホリパーゼｄ４抗体を含む医薬 | |
| BR112014018539B1 (pt) | Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |